Malignant solid neoplasm, MSI-H or dMMR

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 03:13, 23 January 2018 by Warner-admin (talk | contribs) (Text replacement - "font-size:200%"> Hello!<br>  We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.<br>  Please help us by filling it out!<br>" to "font-size:300%"> Just 10 days left to fill out a survey on how we can make HemOnc.org better and more useful.<br>")
Jump to navigation Jump to search

 Just 10 days left to fill out a survey on how we can make HemOnc.org better and more useful.
 Link: http://j.mp/2BlBaoQ


Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

4 regimens on this page
6 variants on this page


Note: this is a new type of page for HemOnc.org, as all other regimen pages (except for cancer of unknown primary) are tissue-specific. The initial drug with tissue-agnostic approval is for patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options.

Pembrolizumab monotherapy

Regimen

Study Evidence
Le et al. 2016 (KEYNOTE-164) Phase II

Note: this is the FDA-approved pembrolizumab dose and schedule based on a pooled analysis of 5 non-randomized trials. This is one representative trial.

Immunotherapy

21-day cycle for up to 2 years

References

  1. Abstract: Dung T. Le, Takayuki Yoshino, Dirk Jäger, Thierry Andre, Johanna C. Bendell, Ruixue Wang... SoonMo Peter Kang, Minori Koshiji, Luis A. Diaz. KEYNOTE-164: Phase II study of pembrolizumab (MK-3475) for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma. J Clin Oncol 2016 abstract TPS787 and abstract TPS3631; NCT02460198 at ClinicalTrials.gov
Retrieved from "https://hemonc.org/w/index.php?title=Malignant_solid_neoplasm,_MSI-H_or_dMMR&oldid=22927"